Rhabdomyosarcoma — the most common soft tissue sarcoma in children and adolescents, arising from primitive mesenchymal cells committed to skeletal muscle differentiation (expressing myogenic markers including desmin, MyoD1, and myogenin/MYOG) and accounting for approximately 50% of all pediatric soft tissue sarcomas and 3–4% of all childhood cancers, with approximately 350–400 new cases diagnosed annually in the United States and a median age at diagnosis of 5–6 years for embryonal subtype and 10–18 years for alveolar subtype — encompasses three major histologic subtypes whose molecular identities have come to define prognosis as decisively as stage and clinical group: embryonal rhabdomyosarcoma (ERMS, representing approximately 57–60% of cases, characterized by relatively favorable prognosis, absence of PAX3/PAX7-FOXO1 fusion, and chromosomal gains at 2q, 8, and 13q), alveolar rhabdomyosarcoma (ARMS, representing approximately 20–25% of cases, defined by PAX3-FOXO1 fusion — from t(2;13)(q35;q14) — in 55–60% of alveolar cases or PAX7-FOXO1 fusion in 20–25%, with PAX3-FOXO1-positive ARMS carrying the most aggressive biology and the designation of high-risk disease regardless of stage), and pleomorphic rhabdomyosarcoma (representing approximately 5% of cases, occurring predominantly in adults and carrying the worst prognosis across subtypes). The primary anatomic distribution of rhabdomyosarcoma — head and neck (orbit, parameningeal including nasopharynx, paranasal sinuses, middle ear, and infratemporal fossa, and non-parameningeal head/neck including parotid and thyroid bed), genitourinary (bladder, prostate, paratesticular, vaginal), and extremity (with the worst metastatic risk of any anatomic subsite) — determines local control strategy, surgical feasibility, and long-term functional outcomes. The foundational treatment paradigm consists of multimodal therapy: chemotherapy with the VAC regimen (vincristine, actinomycin D/dactinomycin, and cyclophosphamide, delivered over 1 year in standard-risk patients with modifications for high-risk and metastatic disease), surgical resection (when achievable with acceptable functional outcomes — important for paratesticular and localized extremity tumors but frequently precluded by anatomic constraints in parameningeal and bladder/prostate locations), and local irradiation (with IMRT or proton beam therapy for parameningeal tumors with meningeal abutment, gross residual disease after surgery, and high-risk alveolar histology). Pediatric oncologists, radiation oncologists delivering IMRT with parameningeal tumor extension protocols, pediatric urologic surgeons coordinating bladder/prostate RMS resection and reconstruction, pediatric ophthalmologists and oculoplastic surgeons managing orbital RMS, otolaryngology-head and neck surgeons managing parameningeal and head/neck non-orbital RMS, molecular pathologists confirming PAX3-FOXO1 or PAX7-FOXO1 fusion status by FISH or RT-PCR, and fertility preservation specialists coordinating oocyte cryopreservation for high-dose cyclophosphamide gonadotoxicity prevention all coordinate care across one of the most complex pediatric oncology management programs in terms of anatomic diversity, local control complexity, and long-term survivorship consequences.
Rhabdomyosarcoma technology platforms — whether supporting pediatric oncology programs coordinating VAC chemotherapy (vincristine, actinomycin D, cyclophosphamide) with cyclophosphamide-associated hemorrhagic cystitis prevention (mesna and hyperhydration protocols), radiation oncology programs delivering IMRT with parameningeal tumor extension margins (including the skull base, meningeal surfaces, and cranial nerve pathways) and proton beam therapy for orbital and parameningeal tumors (offering dosimetric advantages in pediatric patients with developing craniofacial structures and neurocognitive systems at risk), surgical oncology programs coordinating complete gross resection (Group I) or gross total resection with microscopic residuals (Group II) for favorable-site tumors (paratesticular, non-bladder/prostate genitourinary, orbital), pathology programs performing PAX3-FOXO1 and PAX7-FOXO1 FISH or RT-PCR fusion testing (the molecular determinant of alveolar histology classification and high-risk stratification), molecular oncology programs managing vinorelbine/irinotecan salvage chemotherapy for relapsed or refractory disease, irinotecan/temozolomide for Group V metastatic disease, or enrollment in SMARCB1/CDK4/CDK6/IGF1R-targeted trials for fusion-positive alveolar RMS, fertility preservation programs managing oocyte or testicular tissue cryopreservation for prepubertal and pubertal patients facing gonadotoxic cyclophosphamide exposure, or patient portals supporting pediatric rhabdomyosarcoma patients and families managing intensive multi-cycle VAC chemotherapy regimens with complex toxicity profiles across 48–52 weeks of treatment — must maintain the availability and performance standards that rhabdomyosarcoma's pediatric patient population, parameningeal and orbital irradiation complexity, multisite anatomic diversity, PAX fusion molecular stratification requirements, and extended VAC chemotherapy duration demand. This guide explains why rhabdomyosarcoma tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the VAC chemotherapy complexity, parameningeal irradiation precision, and molecular diagnostic requirements of modern rhabdomyosarcoma management.
Why Rhabdomyosarcoma Tech Platforms Require Specialized Monitoring Attention
Rhabdomyosarcoma management is defined by multimodal VAC chemotherapy over 48–52 weeks, IMRT or proton beam therapy for parameningeal and orbital tumors with meningeal extension protocols, surgical resection for favorable anatomic sites, PAX3-FOXO1 and PAX7-FOXO1 molecular fusion testing for risk stratification, cyclophosphamide hemorrhagic cystitis prevention, and fertility preservation coordination. Technology failures in any of these areas create disruptions calibrated to the treatment duration and pediatric functional consequence unique to rhabdomyosarcoma management.
VAC chemotherapy management platforms coordinate a year-long multi-agent regimen. The VAC regimen — vincristine (weekly during active treatment cycles), actinomycin D (delivered as pulse doses with well-documented hepatotoxicity and veno-occlusive disease risk in young children), and cyclophosphamide (with hemorrhagic cystitis prevention requiring mesna premedication and aggressive hyperhydration, and gonadotoxicity affecting oocyte and spermatogonial populations in pubertal and prepubertal patients) — requires platforms managing dosing records across 48–52 weeks of treatment, toxicity surveillance (vincristine neuropathy, actinomycin hepatotoxicity, cyclophosphamide hemorrhagic cystitis and myelosuppression), mesna and hydration protocol documentation, and cycle timing records. Monitor VAC chemotherapy management platforms at 1-minute intervals during business hours and active chemotherapy administration sessions.
Parameningeal IMRT platforms require precision delivery to anatomically complex targets. Parameningeal rhabdomyosarcoma — arising in the nasopharynx, paranasal sinuses, middle ear, infratemporal fossa, and pterygopalatine fossa — requires IMRT with treatment volumes that encompass the primary tumor and any meningeal abutment (meningeal extension defining the Group III parameningeal protocol with whole-brain irradiation or meningeal-based field extension), with dose constraints critical for protecting the developing brain, cranial nerves, cochlea, optic apparatus, pituitary gland, and craniofacial growth centers in young children. Platforms managing parameningeal IMRT treatment plans, meningeal extension protocol documentation, critical structure dose constraints, and daily delivery verification cannot fail during active radiation sessions. Monitor parameningeal IMRT platforms at 1-minute intervals during treatment sessions.
Proton beam therapy platforms serve orbital and craniofacial RMS patients. Orbital rhabdomyosarcoma — where the goal of organ and vision preservation with radiation therapy represents a defining therapeutic achievement (orbital exenteration having been replaced by radiation-based local control in the 1970s) — requires IMRT or proton beam therapy with dose constraints protecting the lens, retina, optic nerve, and orbital contents. Proton therapy's sharper dose fall-off reduces integral dose to developing craniofacial structures in young children. Platforms managing proton treatment planning, beam angle optimization, pencil-beam scanning parameters, and lens dose constraint documentation cannot fail during active treatment sessions. Monitor proton therapy platforms at 1-minute intervals during treatment sessions.
PAX3-FOXO1 and PAX7-FOXO1 molecular diagnostics platforms drive risk stratification. PAX3-FOXO1 fusion — present in 55–60% of alveolar rhabdomyosarcoma cases — is a high-risk molecular marker that drives risk stratification into the high-risk protocol (regardless of stage), influences local control intensity (upfront radiation for all PAX3-FOXO1-positive alveolar RMS), and determines eligibility for high-risk clinical protocols including high-dose chemotherapy with autologous SCT consolidation and IGF1R-targeted or CDK4/6 inhibitor trials. Platforms managing FISH break-apart probe results for FOXO1 rearrangement, RT-PCR PAX3-FOXO1 and PAX7-FOXO1 fusion confirmation, and risk stratification documentation cannot fail during active diagnostic and treatment planning windows. Monitor molecular diagnostics platforms at 1-minute intervals during business hours.
Cyclophosphamide hemorrhagic cystitis prevention platforms require active protocol compliance. High-dose cyclophosphamide — delivered across all VAC cycles with doses ranging from 1.2 to 2.2 g/m² — requires mesna premedication (at doses typically 60–100% of the cyclophosphamide dose, delivered as a fractionated IV or oral regimen before and after cyclophosphamide), aggressive IV hyperhydration, and urinalysis monitoring for hematuria. Platforms managing mesna dosing records, hyperhydration documentation, and hematuria surveillance cannot fail during active cyclophosphamide administration sessions. Monitor hemorrhagic cystitis prevention platforms at 1-minute intervals during active cyclophosphamide sessions.
Fertility preservation platforms coordinate time-sensitive oocyte cryopreservation. High-dose cyclophosphamide — delivered across 48–52 weeks of VAC chemotherapy — is gonadotoxic in prepubertal and pubertal female patients (reducing ovarian follicular reserve) and in pubertal male patients (affecting spermatogonial populations). Fertility preservation consultation and oocyte cryopreservation (for pubertal females) or ovarian tissue cryopreservation (for prepubertal females) must occur before the first cyclophosphamide cycle — a time-sensitive window that requires platform availability for urgent fertility preservation coordination. Monitor fertility preservation platforms during business hours with immediate alerting when consultation is pending prior to chemotherapy initiation.
What to Monitor on a Rhabdomyosarcoma Tech Platform
VAC Chemotherapy Management
Monitor vincristine dosing and peripheral neuropathy surveillance records, actinomycin D pulse dosing and hepatotoxicity monitoring, cyclophosphamide dosing and cumulative dose records, mesna premedication protocol documentation, hyperhydration records, G-CSF administration, cycle timing and delay documentation, and toxicity surveillance (neuropathy, hepatotoxicity, myelosuppression, hematuria) at 1-minute intervals during business hours and active treatment sessions. Alert immediately during active VAC chemotherapy administration.
Parameningeal IMRT Planning and Delivery
Monitor parameningeal IMRT treatment plan access, meningeal extension protocol documentation, whole-brain irradiation field records (when meningeal involvement is documented), critical structure dose constraints (cochlea, optic apparatus, pituitary, brain, craniofacial growth centers), daily delivery verification, and treatment completion records at 1-minute intervals during active treatment sessions. Alert immediately during active parameningeal IMRT delivery windows.
Proton Beam Therapy (Orbital and Craniofacial RMS)
Monitor proton beam treatment planning documentation, orbital lens and retina dose constraint records, pencil-beam scanning parameters, critical structure dose constraint compliance, daily delivery verification, and vision-preservation outcome documentation at 1-minute intervals during active treatment sessions. Alert immediately during active proton therapy delivery.
PAX3-FOXO1 and PAX7-FOXO1 Molecular Diagnostics
Monitor FOXO1 FISH break-apart probe test ordering and result routing, RT-PCR PAX3-FOXO1 and PAX7-FOXO1 fusion confirmation, fusion-positive alveolar RMS high-risk protocol assignment documentation, and clinical trial eligibility records at 1-minute intervals during business hours. Alert immediately — molecular stratification access failures delay risk-adapted protocol assignment in a disease where alveolar fusion status determines the intensity of local and systemic treatment.
Cyclophosphamide Hemorrhagic Cystitis Prevention
Monitor mesna premedication dosing records and administration confirmation, hyperhydration volume and rate documentation, urinalysis and hematuria surveillance records, and hemorrhagic cystitis intervention escalation at 1-minute intervals during active cyclophosphamide administration sessions. Alert immediately during active cyclophosphamide sessions — mesna documentation failures risk hematuria management delays.
Fertility Preservation Coordination
Monitor fertility preservation consultation scheduling, oocyte cryopreservation procedure coordination (for pubertal females requiring retrieval before first cyclophosphamide cycle), ovarian tissue cryopreservation scheduling (for prepubertal females), semen cryopreservation coordination (for pubertal male patients), and post-treatment ovarian function surveillance during business hours. Alert on sustained failures when fertility preservation is urgently pending prior to chemotherapy initiation.
Surgical Resection Coordination
Monitor surgical resection planning records (paratesticular, orbital, genitourinary, extremity), intraoperative margin documentation, Group I/II/III clinical grouping assignment, second-look surgery scheduling (for select Group III patients following induction), and post-operative rehabilitation records at 1-minute intervals during business hours and operative windows. Alert immediately during active operative sessions.
Relapse and Salvage Chemotherapy Management
Monitor vinorelbine/irinotecan or irinotecan/temozolomide salvage chemotherapy dosing records for relapsed/refractory disease, targeted therapy trial records (IGF1R inhibitors, CDK4/6 inhibitors, larotrectinib for NTRK-rearranged cases), and palliative care coordination at 1-minute intervals during business hours and active salvage therapy sessions. Alert immediately — salvage therapy access failures affect patients with limited treatment options after VAC failure.
Long-Term Surveillance and Late Effects Monitoring
Monitor post-treatment surveillance imaging scheduling (chest CT, MRI of primary site), endocrine function monitoring (pituitary and gonadal axis surveillance for patients who received craniofacial and gonadal-field radiation), audiologic surveillance (for patients who received cochlear radiation field during parameningeal IMRT), musculoskeletal growth monitoring for patients treated during craniofacial growth periods, and secondary malignancy surveillance during business hours. Alert on sustained failures — late effects monitoring gaps in childhood cancer survivors affect long-term quality of life in patients who may live 60+ years post-diagnosis.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Rhabdomyosarcoma programs coordinate across pediatric oncology, radiation oncology, pediatric surgery, molecular pathology, ophthalmology, urology, endocrinology, fertility preservation, and audiology — authentication failures simultaneously block every member of a care team managing pediatric patients on 48–52 weeks of VAC chemotherapy where cyclophosphamide administration, mesna protocols, and PAX fusion status records require continuous, coordinated multi-specialty platform access.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all patient portals, VAC chemotherapy management systems, IMRT and proton therapy platforms, molecular diagnostics interfaces, fertility preservation coordination systems, surgical planning platforms, and long-term surveillance imaging portals. Certificate errors disrupt the chemotherapy administration and craniofacial irradiation workflows critical to rhabdomyosarcoma management.
HIPAA and Oncology Data Privacy Considerations
Rhabdomyosarcoma technology platforms handle sensitive PHI including PAX3-FOXO1 and PAX7-FOXO1 molecular fusion records in pediatric patients (with heightened HIPAA minor-patient protections and potential implications for family screening in rare PAX-associated familial sarcoma contexts), cyclophosphamide hemorrhagic cystitis prevention records with hematuria surveillance documentation, fertility preservation records including oocyte cryopreservation and ovarian tissue storage data for prepubertal and pubertal female patients (with heightened sensitivity given reproductive implications), parameningeal IMRT records with meningeal extension protocol documentation and craniofacial growth center dose constraint records, VAC chemotherapy dosing records across 48–52 weeks of treatment, late effects monitoring records spanning decades post-treatment, and secondary malignancy surveillance data in long-term childhood cancer survivors. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components, with heightened provisions governing pediatric patient records, fertility preservation PHI, and decade-spanning late effects surveillance data.
For platforms managing cyclophosphamide hemorrhagic cystitis prevention records — where documentation gaps during mesna administration could contribute to hematuria management delays — data availability standards must match the active treatment administration dependency. For platforms managing fertility preservation records that protect the reproductive future of prepubertal and pubertal pediatric cancer patients, privacy and availability standards must reflect the unique clinical and personal significance of these records. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for rhabdomyosarcoma programs managing sensitive pediatric oncology PHI across extended treatment and surveillance intervals.
Alerting Strategy for Rhabdomyosarcoma Tech Platforms
Immediate alerting during treatment and administration sessions: VAC chemotherapy management during active vincristine, actinomycin D, and cyclophosphamide sessions; cyclophosphamide hemorrhagic cystitis prevention protocols during active cyclophosphamide administration; parameningeal IMRT delivery during active treatment sessions; proton beam therapy during active orbital/craniofacial treatment. These platforms cannot fail during active administration and delivery.
Immediate business-hours alert: PAX3-FOXO1 and PAX7-FOXO1 molecular diagnostics (risk stratification decisions), fertility preservation coordination (time-sensitive prior to first cyclophosphamide cycle), surgical resection planning (during operative windows), and relapse/salvage chemotherapy management. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Long-term late effects surveillance scheduling, post-treatment surveillance imaging, endocrine and audiologic monitoring, patient communication portal, and secondary malignancy surveillance. Alert when failures persist beyond a single workflow cycle.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms rhabdomyosarcoma platform availability from the geographies where pediatric oncology centers, parameningeal radiation programs, proton beam therapy centers, fertility preservation centers, and long-term survivor late effects clinics access the system — important for platforms supporting patients who travel to specialized rhabdomyosarcoma centers for proton therapy or orbital RMS management and return to regional institutions for ongoing VAC chemotherapy administration.
Status Page for Rhabdomyosarcoma Care Team Communication
A real-time status page gives pediatric oncology nurses administering VAC chemotherapy cycles, radiation therapists delivering parameningeal IMRT with meningeal extension protocols, proton therapy physicists verifying orbital lens dose constraints, molecular pathologists routing PAX3-FOXO1 fusion results, urologic surgeons coordinating paratesticular resection, fertility preservation specialists coordinating oocyte cryopreservation before cyclophosphamide initiation, and late effects clinic providers monitoring craniofacial growth and endocrine function immediate platform visibility without requiring inbound IT support contact. During a VAC chemotherapy management platform outage during an active cyclophosphamide administration session, a status page enables the oncology nursing team to immediately activate paper-based mesna and hyperhydration documentation protocols — ensuring that hemorrhagic cystitis prevention documentation proceeds without platform-dependent records access during the administration window.
Include the status page URL in VAC chemotherapy downtime procedures, parameningeal IMRT treatment fallback protocols, proton therapy contingency workflows, fertility preservation emergency coordination procedures, and PAX molecular diagnostics emergency access workflows.
Vigilmon Setup for Rhabdomyosarcoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | VAC chemotherapy management (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Cyclophosphamide mesna / cystitis prevention (active sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Parameningeal IMRT (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | Proton beam therapy — orbital / craniofacial (treatment sessions) | 1 min | Slack + PagerDuty (treatment hours) | | PAX3-FOXO1 / PAX7-FOXO1 molecular diagnostics | 1 min | Slack + PagerDuty (business hours) | | Fertility preservation coordination | 1 min | Slack + PagerDuty (business hours) | | Surgical resection coordination (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | Relapse / salvage chemotherapy management | 1 min | Slack + PagerDuty (business hours) | | Long-term late effects / surveillance imaging | 2 min | Slack (business hours) | | Patient and family communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure VAC chemotherapy management with immediate alerting during active treatment sessions
- Add cyclophosphamide hemorrhagic cystitis prevention with immediate alerting during active cyclophosphamide administration
- Configure parameningeal IMRT with immediate alerting during active treatment sessions
- Add proton beam therapy (orbital/craniofacial) with immediate alerting during treatment sessions
- Configure PAX3-FOXO1 and PAX7-FOXO1 molecular diagnostics with immediate business-hours alerting
- Add fertility preservation coordination with immediate alerting when pre-chemotherapy consultation is pending
- Configure surgical resection coordination with immediate alerting during operative windows
- Add relapse and salvage chemotherapy management with immediate business-hours alerting
- Configure long-term late effects and surveillance imaging with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, chemotherapy, IMRT, proton therapy, molecular diagnostics, and fertility preservation domains
- Add the status page URL to VAC chemotherapy downtime procedures, IMRT treatment fallback protocols, and fertility preservation emergency procedures
Conclusion
Rhabdomyosarcoma technology platforms are embedded in clinical decisions where parameningeal IMRT delivery platform availability during an active treatment session for a seven-year-old with a nasopharyngeal rhabdomyosarcoma with meningeal abutment determines whether the radiation oncologist can verify that the day's dose fraction — part of a 50.4 Gy course shaped by a treatment plan that concentrates dose on the primary parameningeal tumor and its meningeal extension while respecting the brainstem, cochlea, pituitary gland, and optic apparatus dose constraints that protect the developing neurocognitive function, hearing, endocrine axis, and vision of a child whose survival is the goal but whose quality of life across the seventy years of survivorship that cure may provide is equally the clinician's responsibility — can be delivered and verified before the child enters the treatment room, rather than during an unmonitored platform failure that delays a fraction of a course for which interruptions beyond ten days significantly reduce local control probability — where PAX3-FOXO1 molecular diagnostics platform availability in the week following alveolar rhabdomyosarcoma diagnosis determines whether the risk stratification that assigns this child to the high-risk protocol with intensified chemotherapy and upfront irradiation — a protocol reserved for fusion-positive alveolar histology given the toxicity burden it carries — can be confirmed from the molecular result before the first treatment cycle is initiated, rather than after two cycles of standard-risk VAC that would have to be interrupted and replaced with high-risk protocol therapy if the fusion status returns positive at a delayed diagnostic access point — and where fertility preservation coordination platform availability in the days between cyclophosphamide-based VAC initiation scheduling and the first administration session determines whether the pubertal female patient with localized paratesticular rhabdomyosarcoma can be urgently referred for oocyte cryopreservation before the cumulative gonadotoxic cyclophosphamide exposure that will accompany 48 weeks of VAC chemotherapy reduces her ovarian reserve, preserving a reproductive future that the cure of her cancer should not be required to foreclose. A parameningeal IMRT platform that fails during an active treatment session when meningeal extension protocol verification is required, a PAX3-FOXO1 molecular platform inaccessible when risk stratification must be confirmed before high-risk protocol initiation, a fertility preservation coordination platform unavailable when a pubertal female faces the time-limited window between chemotherapy scheduling and first cyclophosphamide administration within which oocyte cryopreservation is medically feasible — these are not IT incidents. They are clinical disruptions in the management of the most common pediatric soft tissue malignancy, where platform availability shapes the radiation precision that determines orbital preservation in a four-year-old, the molecular accuracy that determines the treatment intensity a child will endure, and the fertility preservation access that determines whether a teenage girl cured of cancer will have the option to become a biological mother.
Uptime monitoring gives rhabdomyosarcoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric oncology programs, parameningeal radiation programs, proton therapy centers, and compliance auditors that the platform's operational reliability matches the VAC chemotherapy complexity, parameningeal irradiation precision, and fertility preservation urgency of modern rhabdomyosarcoma management.
Start monitoring your rhabdomyosarcoma tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #rhabdomyosarcoma #softtissuesarcoma #pediatriconcology #VACchemotherapy #PAX3FOXO1 #PAX7FOXO1 #parameningeal #IMRT #protontherapy #orbitalRMS #cyclophosphamide #mesna #fertilitypreservation #alveolarRMS #embryonalRMS #moleculardiagnostics #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre